Tripep raises SEK 24 million through a rights issue

Tripep raises SEK 24 million through a rights issue

The Board of Directors of Tripep AB (publ.) has resolved to convene an
Extraordinary General meeting to be held on 19 December, 2007 in order to
present, as previously announced, a proposal for a new issue. The new issue will
be a rights issue and will raise SEK 24.1 million excluding costs, which are
estimated to SEK 1.9 million. The subscription of the new issue has been fully
secured through subscription undertakings and guarantee agreements.

Background
The capital from the rights issue secures the continuation of the phase I/II
study of 
ChronVac-C® and the initiation of the phase II study of ChronSeal and start GMP
manufacturing of ChronVac-B. The capital raised will make it possible for the
company to continue its operations to the third quarter of 2008. Further capital
may be raised through the warrants if the company's value develops positively.
This capital raised through the warrants will be used to the further development
of these projects and furthermore gives the company an operating reserve.

Rights issue
The Board of Directors proposes the following terms and conditions for the new
issue
•	The number of shares to be issued shall not exceed 48,260,870
•	The subscription price shall be SEK 0.50 per share
•	Each existing share shall entitle to subscription for one new share
•	For each subscribed share a warrant will be received at no cost. Two warrants
entitle the holder to subscribe for one new share at SEK 1.00 during the period
1 April, 2008 - 30 September, 2009. A maximum of 48,260,870 warrants will be
issued, which will entitle to subscribe for a maximum of 24,130,435 shares. If
all warrants are exercised the Company will raise another approx. SEK 24.1
million.
•	The subscription of the new issue is fully secured through subscription
undertakings and guarantees issued by Erik Selin Fastigheter AB, Rutger Smith
and Thomas Lynch.

Time plan for the new issue
•	Last day for trading in the share including the right to participate in the
new issue is 7 January, 2008
•	The record date is 10 January 2008
•	A prospectus is expected to be announced around 21 December, 2007.
•	The period for subscription with pre-emption rights is 16 - 30 January, 2008
•	Trading in subscription rights takes place during the period 16 - 25 January,
2008
The notice of the EGM is attached to this press release.


For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .